专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20090060910A1 COVALENT DIABODIES AND USES THEREOF 有权
标题翻译：同性双胞胎及其用途
公开(公告)号：US20090060910A1
公开(公告)日：2009-03-05
申请号：US12138867
申请日：2008-06-13
申请人： Leslie S. JOHNSON , Ling HUANG
发明人： Leslie S. JOHNSON , Ling HUANG
IPC分类号： A61K39/395 , C07K16/30 , A61P35/00
CPC分类号： C07K16/283 , C07K2317/34 , C07K2317/52 , C07K2317/626
摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
摘要翻译：本发明涉及双抗体分子及其在治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）中的用途。本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。另外，抗原可以来自相同或不同的分子。双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。在具体实施方案中，本发明的双抗体分子还包含Fc区，其允许抗体样功能被改造成分子。

12. 发明授权

US09587021B2 CD3-binding molecules capable of binding to human and non-human CD3 有权
标题翻译：能结合人和非人CD3的CD3结合分子
公开(公告)号：US09587021B2
公开(公告)日：2017-03-07
申请号：US14118523
申请日：2012-05-16
申请人： Ling Huang , Leslie S. Johnson
发明人： Ling Huang , Leslie S. Johnson
IPC分类号： A61K39/395 , C07K16/28 , C07K16/32
CPC分类号： C07K16/2809 , C07K16/2803 , C07K16/2827 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： CD3-binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey) are presented. Uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions are presented.
摘要翻译：提供能够结合人和非人CD3，特别是与非人哺乳动物（例如食蟹猴）与CD3交叉反应的分子的CD3结合分子。提出了这些抗体和抗原结合片段在治疗癌症，自身免疫和/或炎性疾病和其他病症中的用途。

13. 发明申请

US20140328836A1 HER2/neu-Specific Antibodies and Methods of Using Same 有权
标题翻译： HER2 / neu特异性抗体及其使用方法
公开(公告)号：US20140328836A1
公开(公告)日：2014-11-06
申请号：US14332239
申请日：2014-07-15
申请人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
发明人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
IPC分类号： C07K16/32 , A61K39/395 , A61K45/06
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及与已知的4D5抗体相比具有降低的糖基化的HER2 / neu特异性结合HER2 / neu的嵌合4D5抗体的抗体。本发明还涉及将4D5抗体及其组合物用于诊断，预后和治疗疾病如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的方法。

14. 发明授权

US08802093B2 HER2/neu-specific antibodies and methods of using same 有权
标题翻译： HER2 / neu特异性抗体及其使用方法
公开(公告)号：US08802093B2
公开(公告)日：2014-08-12
申请号：US12933885
申请日：2009-03-25
申请人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
发明人： Leslie S. Johnson , Ling Huang , Nadine Tuaillon , Ezio Bonvini
IPC分类号： A61K39/395 , A61P35/04 , C07K16/28
CPC分类号： C07K16/32 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/71 , C07K2317/732 , C07K2317/92
摘要： This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及与已知的4D5抗体相比具有降低的糖基化的HER2 / neu特异性结合HER2 / neu的嵌合4D5抗体的抗体。本发明还涉及将4D5抗体及其组合物用于诊断，预后和治疗疾病如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的方法。

15. 发明申请

US20120219551A1 Fc Region-Containing Polypeptides That Exhibit Improved Effector Function Due To Alterations Of The Extent Of Fucosylation, And Methods For Their Use 有权
标题翻译：含有Fc区域的多肽，其展示了由于岩藻糖基化程度的改变而产生的改善效应的功能，以及它们使用的方法
公开(公告)号：US20120219551A1
公开(公告)日：2012-08-30
申请号：US13499007
申请日：2010-10-07
申请人： Leslie S. Johnson , Godfrey Jonah Anderson Rainey , Sergey Gorlatov , Laura Lerner
发明人： Leslie S. Johnson , Godfrey Jonah Anderson Rainey , Sergey Gorlatov , Laura Lerner
IPC分类号： A61K39/395 , C07K16/30 , A61P35/00 , C12P21/00
CPC分类号： C12P21/005 , A61K2039/505 , C07K16/283 , C07K16/2887 , C07K16/32 , C07K16/44 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and to methods of using such polypeptides for treating or preventing cancer and other diseases. The Fc region-containing polypeptides of the present invention are preferably immunoglobulins (e.g., antibodies), in which the Fc region comprises at least one amino acid substitution relative to the corresponding amino acid sequence of a wild type Fc region, and which is sufficient to attenuate post-translational fucosylation and mediate improved binding to an activating Fc receptor and reduced binding to an inhibitory Fc receptor. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by FcγR is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by FcγR is desired (e.g., inflammation, autoimmune disease).
摘要翻译：本发明涉及由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽，以及使用这些多肽来治疗或预防癌症和其它疾病的方法。本发明的含Fc区的多肽优选为免疫球蛋白（例如抗体），其中Fc区包含相对于野生型Fc区的相应氨基酸序列的至少一个氨基酸取代，其足以减弱翻译后岩藻糖基化并介导改善的与活化Fc受体的结合并降低与抑制性Fc受体的结合。本发明的方法特别可用于预防，治疗或改善与需要由FcγR介导的效应细胞功能的增强功效的疾病，病症或感染相关的一种或多种症状（例如癌症，感染性疾病）或由FcγR介导的受抑制的效应细胞反应是期望的（例如炎症，自身免疫性疾病）。

16. 发明授权

US08153133B2 High potency recombinant antibodies and method for producing them 失效
标题翻译：高效重组抗体及其制备方法
公开(公告)号：US08153133B2
公开(公告)日：2012-04-10
申请号：US12707527
申请日：2010-02-17
申请人： James F. Young , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
发明人： James F. Young , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
IPC分类号： A61K39/42
CPC分类号： C07K16/1027 , A61K2039/505 , C07K16/00 , C07K2317/567
摘要： High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
摘要翻译：公开了具有高动力学关联速率常数和任选的高亲和力的高效力抗体，包括其免疫活性片段，以及产生此类抗体的方法。本文公开的高效力抗体是中和或非中和型，并且对由微生物，特别是病毒以及存在于癌细胞和各种类型毒素上的抗原位点以及毒素产物显示的抗原具有特异性。还描述了用于产生高效中和抗体并增加已经存在的中和抗体的效力的方法。公开了在预防和/或治疗疾病，特别是由病毒引起或引起的疾病中使用所述抗体的方法。

17. 发明授权

US08133982B2 FcγRIIB specific antibodies and methods of use thereof 有权
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08133982B2
公开(公告)日：2012-03-13
申请号：US12349876
申请日：2009-01-07
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： C07K16/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition.
摘要翻译：本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导平衡失去相关的任何疾病（例如癌症（优选B细胞恶性肿瘤，特别是B细胞慢性淋巴细胞性白血病或非 - 霍奇金淋巴瘤），自身免疫性疾病，炎性疾病或IgE介导的过敏性疾病。本发明还包括与其它癌症疗法组合的人源化FcγRIIB抗体或其抗原结合片段的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过用疫苗组合物施用本发明的人源化抗体来增强疫苗组合物的功效的方法。

18. 发明授权

US07847082B2 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 失效
标题翻译：给予/给予抗RSV抗体进行预防和治疗的方法
公开(公告)号：US07847082B2
公开(公告)日：2010-12-07
申请号：US12476183
申请日：2009-06-01
申请人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
发明人： James F. Young , Scott Koenig , Leslie S. Johnson , William D. Huse , Jeffrey D. Watkins , Herren Wu
IPC分类号： C07H21/04 , A61K39/42 , A61K39/155
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
摘要翻译：本发明包括免疫特异性结合一种或多种RSV抗原的新型抗体及其片段，以及包含所述抗体和抗体片段的组合物。本发明包括预防人类呼吸道合胞病毒（RSV）感染的方法，包括向所述人施用预防有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定的血清滴度为所述抗体或抗体片段在所述人受试者中实现。本发明还包括用于治疗或改善与人类RSV感染有关的症状的方法，包括向所述人施用治疗有效量的一种或多种免疫特异性结合一种或多种RSV抗原的抗体或其片段，其中一定所述抗体或抗体片段的血清滴度在所述人受试者中实现。本发明还包括包含免疫特异性结合RSV抗原的抗体或其片段的组合物，以及使用所述组合物检测或诊断RSV感染的方法。

19. 发明申请

US20100266614A1 ULTRA HIGH AFFINITY NEUTRALIZING ANTIBODIES 审中-公开
标题翻译：超高抗中性抗体
公开(公告)号：US20100266614A1
公开(公告)日：2010-10-21
申请号：US12777814
申请日：2010-05-11
申请人： James F. YOUNG , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
发明人： James F. YOUNG , Leslie S. Johnson , William D. Huse , Herren Wu , Jeffry D. Watkins
IPC分类号： A61K39/42 , C07K16/08 , A61P31/12
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1027 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
摘要翻译：公开了具有1010M-1甚至1011M-1范围内的结合亲和力的超高亲和力抗体。此类抗体包括具有新型高亲和力互补决定区（CDR）的抗体，特别是具有来自人或小鼠的骨架和恒定区的抗体。还公开了制备和筛选这些抗体的方法，以及使用它们来预防和/或治疗疾病，特别是病毒诱导的疾病的方法。

20. 发明申请

US20090324593A1 Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof 审中-公开
标题翻译：针对西尼罗河病毒的人源化抗体及其治疗和预防用途
公开(公告)号：US20090324593A1
公开(公告)日：2009-12-31
申请号：US12457447
申请日：2009-06-11
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395 , C07K16/00 , C12Q1/70 , A61P31/12
CPC分类号： C07K16/1081 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G01N33/56983 , G01N2333/18 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/396 , Y02A50/53 , Y02A50/60
摘要： The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV. antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
摘要翻译：本发明涉及包含人源化抗体或其片段的组合物，其免疫特异性结合黄病毒，特别是西尼罗病毒（WNV）的一种或多种抗原，以及用于预防，治疗或改善与黄病毒特别是西尼罗病毒有关的症状的方法利用所述组合物的病毒（WNV）感染。特别地，本发明涉及用于预防，治疗或改善与WNV感染相关的症状的方法，所述方法包括向人受体施用有效量的一种或多种免疫特异性结合WNV抗原的人源化抗体或其片段。本发明还涉及包含免疫特异性结合WNV的人源化抗体或其片段的可检测或诊断组合物。抗原和利用所述组合物检测或诊断WNV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式